

References

I-241

1. National Comprehensive Cancer Network (NCCN). Amivantamab NCCN Drugs and Biologics Compendium®. 2024.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Amivantamab.
3. Micromedex DrugDex Compendium®. 2024. Amivantamab-vmjw.
4. Amivantamab-vmjw injection, for intravenous use [package insert]. Janssen Biotech, Inc. Horsham, PA. Revised 08/2024
5. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/ macrophage trogocytosis. *Mol Cancer Ther.*2020;19:2044-2056.
6. Yun J, Lee SH, Kim SY, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. *Cancer Discov.* 2020;10(8):1194-1209.
7. Sabari JK, Shu CA, Park K, et al. Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer [abstract]. *J Thorac Oncol.*2021;16(3S)108-109.
8. Amivantamab-vmjw In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 7, 2021.
9. Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with *EGFR* Exon 20 Insertions. *N Engl J Med.* 2023;389(22):2039-2051.
10. Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. *Future Oncol.* 2022;18(6):639-647.